Literature DB >> 22416021

Effectiveness of sequencing selected exons of DNAH5 and DNAI1 in diagnosis of primary ciliary dyskinesia.

Jana Djakow1, Tamara Svobodová, Karel Hrach, Jiří Uhlík, Ondřej Cinek, Petr Pohunek.   

Abstract

INTRODUCTION: Primary ciliary dyskinesia (PCD) is a rare genetically heterogenous condition. Mutations in DNAH5 or DNAI1 genes can be found in about a third of the patients with PCD. Increased occurrence of mutations was described in several exons of these long genes. The objective of the study was to test the sensitivity of sequencing of selected 13 exons (as compared to costly sequencing of all 100 exons of the two genes), and to determine the prevalence of the DNAH5 or DNAI1 mutations in the Czech PCD database.
METHODS: The Czech national PCD database has identified 31 pediatric patients, diagnosed based on clinical findings and tests on the ciliated epithelium. Twenty-seven patients from 24 families agreed on genetic testing. In the first step, direct sequencing of selected 13 exons (9 of DNAH5 and 4 of DNAI1) was performed, and then we compared its effectiveness in detecting at least one mutation with results of sequencing all 100 exons of the two genes.
RESULTS: The sequencing of all exons identified compound heterozygosity for PCD mutations in nine patients from eight families (DNAH5 in eight and DNAI1 in one patient), and heterozygozity for a DNAH5 mutation of uncertain functional significance in one additional patient. The first step of selected exon sequencing detected a mutation in five out of these eight families, its actual sensitivity being 62.5%, with a high predictive value. The phenotypic and clinical characteristics of all the paediatric patients with PCD are shown.
CONCLUSIONS: Selected exon sequencing detects at least one mutated allele in over a half of our patients who have PCD due to DNAH5 or DNAI1 mutations. To lower the costs of the genetic testing, targeted step-wise genetic testing may be a reasonable approach to detect mutations in PCD patients, especially if their phenotype is taken into account.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22416021     DOI: 10.1002/ppul.22520

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  20 in total

1.  Mutation analysis in patients with total sperm immotility.

Authors:  Rute Pereira; Jorge Oliveira; Luis Ferraz; Alberto Barros; Rosário Santos; Mário Sousa
Journal:  J Assist Reprod Genet       Date:  2015-04-16       Impact factor: 3.412

2.  Clinical and genetic analysis of a family with Kartagener syndrome caused by novel DNAH5 mutations.

Authors:  Xuan Xu; Ping Gong; Jie Wen
Journal:  J Assist Reprod Genet       Date:  2016-12-17       Impact factor: 3.412

Review 3.  Prevalence of primary ciliary dyskinesia in consecutive referrals of suspect cases and the transmission electron microscopy detection rate: a systematic review and meta-analysis.

Authors:  Panayiotis Kouis; Panayiotis K Yiallouros; Nicos Middleton; John S Evans; Kyriacos Kyriacou; Stefania I Papatheodorou
Journal:  Pediatr Res       Date:  2016-12-09       Impact factor: 3.756

4.  Novel DNAAF6 variants identified by whole-exome sequencing cause male infertility and primary ciliary dyskinesia.

Authors:  Ying Wang; Chaofeng Tu; Hongchuan Nie; Lanlan Meng; Dongyan Li; Weili Wang; Huan Zhang; Guangxiu Lu; Ge Lin; Yue-Qiu Tan; Juan Du
Journal:  J Assist Reprod Genet       Date:  2020-03-13       Impact factor: 3.412

5.  The role of molecular genetic analysis in the diagnosis of primary ciliary dyskinesia.

Authors:  Raymond H Kim; David A Hall; Ernest Cutz; Michael R Knowles; Kathleen A Nelligan; Keith Nykamp; Maimoona A Zariwala; Sharon D Dell
Journal:  Ann Am Thorac Soc       Date:  2014-03

6.  A novel mutation of the axonemal dynein heavy chain gene 5 (DNAH5) in a Japanese neonate with asplenia syndrome.

Authors:  Genshu Tate; Takuma Tajiri; Koji Kishimoto; Toshiyuki Mitsuya
Journal:  Med Mol Morphol       Date:  2014-06-10       Impact factor: 2.309

7.  A novel DNAH5 variant in a Tunisian patient with primary ciliary dyskinesia.

Authors:  Rahma Mani; JihèNe Bouguila; Salma Ben Ameur; Mongia Hachicha; Zohra Soua; Imed Mabrouk
Journal:  J Genet       Date:  2020       Impact factor: 1.166

8.  European Respiratory Society guidelines for the diagnosis of primary ciliary dyskinesia.

Authors:  Jane S Lucas; Angelo Barbato; Samuel A Collins; Myrofora Goutaki; Laura Behan; Daan Caudri; Sharon Dell; Ernst Eber; Estelle Escudier; Robert A Hirst; Claire Hogg; Mark Jorissen; Philipp Latzin; Marie Legendre; Margaret W Leigh; Fabio Midulla; Kim G Nielsen; Heymut Omran; Jean-Francois Papon; Petr Pohunek; Beatrice Redfern; David Rigau; Bernhard Rindlisbacher; Francesca Santamaria; Amelia Shoemark; Deborah Snijders; Thomy Tonia; Andrea Titieni; Woolf T Walker; Claudius Werner; Andrew Bush; Claudia E Kuehni
Journal:  Eur Respir J       Date:  2017-01-04       Impact factor: 16.671

9.  Whole-exome sequencing reveals a combination of extremely rare single-nucleotide polymorphism of DNAH9 and RSPH1 genes in a Japanese fetus with situs viscerum inversus.

Authors:  Genshu Tate
Journal:  Med Mol Morphol       Date:  2021-05-18       Impact factor: 2.309

10.  Exome sequencing identifies DYNC2H1 mutations as a common cause of asphyxiating thoracic dystrophy (Jeune syndrome) without major polydactyly, renal or retinal involvement.

Authors:  Miriam Schmidts; Heleen H Arts; Ernie M H F Bongers; Zhimin Yap; Machteld M Oud; Dinu Antony; Lonneke Duijkers; Richard D Emes; Jim Stalker; Jan-Bart L Yntema; Vincent Plagnol; Alexander Hoischen; Christian Gilissen; Elisabeth Forsythe; Ekkehart Lausch; Joris A Veltman; Nel Roeleveld; Andrea Superti-Furga; Anna Kutkowska-Kazmierczak; Erik-Jan Kamsteeg; Nursel Elçioğlu; Merel C van Maarle; Luitgard M Graul-Neumann; Koenraad Devriendt; Sarah F Smithson; Diana Wellesley; Nienke E Verbeek; Raoul C M Hennekam; Hulya Kayserili; Peter J Scambler; Philip L Beales; Nine Vam Knoers; Ronald Roepman; Hannah M Mitchison
Journal:  J Med Genet       Date:  2013-03-01       Impact factor: 5.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.